Theoretical Analysis of Genome Therapy Colon Cancer via CRISPR-Cas9

SCIENTIFIC ANNOUNCEMENT Title: «CRISPR-CRCcorrect: A Genome Repair Approach in the Fight Against Colorectal Cancer» Lead Researcher: Dr. Dimitris Kimoglou Field of Research: Theoretical Neuroscience & Bioinformatics Date: February 15, 2026 Biochemical and Molecular Description of the Study This research evaluates the therapeutic intervention in colorectal cancer (CRC) through genomic reprogramming utilizing the CRISPR-CRCcorrect system. The analysis focuses on the chemical affinity and molecular dynamics of the following mechanisms: Ribonucleoprotein (RNP) Complex Formation: The strategy is based on the conjugation of the Cas9 endonuclease with a precision-engineered sgRNA, which identifies target sequences in the APC, KRAS, and TP53 oncogenes through complementary hydrogen bonding. +1 Double-Strand Break (DSB) Engineering: The Cas9 enzyme induces precise hydrolysis of the phosphodiester bonds within the DNA backbone, creating a target site exactly three nucleotides upstream of the PAM (Protospacer Adjacent Motif) sequence. +3 Enzymatic Kinetics of Homology-Directed Repair (HDR): The study proposes the exploitation of the HDR pathway for faithful restoration of genetic information. Exogenous ssODN (Single-Stranded Oligodeoxynucleotides) serve as chemical templates, guiding sequence re-synthesis without the introduction of stochastic mutations (indels). +4 Transcriptional Reprogramming and Proteomics: The biochemical correction of mutations leads to the inhibition of nuclear β-catenin accumulation (via the restoration of the APC destruction complex), causing a drastic down-regulation in the expression of transcription factors c-MYC and Cyclin D1. +1 Apoptotic Cascade Activation: The restoration of the TP53 gene reinstates the "guardian of the genome" function, triggering the chemical sequence of caspases (Caspase-3/7) and inducing programmed cell death in malignant cells. +2 Molecular Targeting and Quality of Life: The high selectivity of the method minimizes "off-target" effects, which biochemically translates to reduced cytotoxicity and clinically to a projected improvement in Quality of Life (EORTC QLQ-C30) by 33-40%. +2